Indications of Genazopt Ophthalmic Solution

Brinzolamide Ophthalmic Suspension is used to treat high intraocular pressure in ocular hypertension or open-angle glaucoma as a monotherapy or as an additional therapy to beta-blockers.

Pharmacology of Genazopt Ophthalmic Solution

Carbonic anhydrase (CA) is an enzyme that may be found in a variety of bodily tissues, including the eye. It catalyzes the reversible process of carbon dioxide hydration followed by carbonic acid dehydration. Carbonic anhydrase II (CA-II), which is present predominantly in red blood cells but also in other tissues, is the most active isoenzyme. Carbonic anhydrase inhibition in the ciliary processes of the eye reduces aqueous humor secretion, probably by delaying the production of bicarbonate ions and hence sodium and fluid transfer.

Brinzolamide suppresses aqueous humor formation and lowers increased intraocular pressure after topical ocular application. In the pathophysiology of optic nerve injury and glaucomatous visual field loss, elevated intraocular pressure is a key risk factor.

Dosage & Administration of Genazopt Ophthalmic Solution

One drop of this eye drop in the conjunctival sac of the afflicted eye(s) twice a day is the suggested dose. One drop three times a day may be more effective for some individuals. Before using it, give it a good shake.

Interaction of Genazopt Ophthalmic Solution

Rare incidences of medication interactions with high-dose salicylate treatment have occurred in patients treated with oral carbonic anhydrase inhibitors. As a result, patients using Brinzolamide should be aware of the possibility of such medication interactions.

Contraindications

It is contraindicated in patients who are hypersensitive to any component of this product.

Side Effect of Genazopt Ophthalmic Solution

Reported side effects are blurred vision and bitter, sour, or unusual taste. Other side effects are blepharitis, dermatitis, dry eye, foreign body sensation, headache, hyperemia, ocular discharge, ocular discomfort, ocular keratitis, ocular pain, ocular pruritus, and rhinitis.

Pregnancy & Lactation

Category C pregnancy. In pregnant women, there are no appropriate and well-controlled trials. Only if the benefit outweighs the danger to the fetus should Brinzolamide 1 percent ophthalmic suspension be used during pregnancy.

Brinzolamide 1 percent ophthalmic suspension is not known to be excreted in human milk when used during breastfeeding. As a result, lactating mothers should either stop breastfeeding or stop taking the medication, depending on how important the drug is to the mother.

Precautions & Warnings

• Brinzolamide ophthalmic suspension and its metabolite are excreted predominantly by the kidney. So, it is not recommended in severe renal impaired patients.
• Brinzolamide ophthalmic suspension has not been studied in patients with hepatic impairment and should be used with caution in such patients.
• The concomitant administration of Brinzolamide ophthalmic suspension and oral carbonic anhydrase inhibitor is not recommended due to no additional benefits.
• If a hypersensitivity reaction occurs after instillation patients should be advised to discontinue the use of Brinzolamide and consult with physicians.

Therapeutic Class

Drugs for miotics and glaucoma

Storage Conditions

Store at room temperature and keep away from direct sunlight. Do not let the dropper tip come into contact with any surface. It’s best if the contents aren’t utilized for more than four weeks after the bottle is initially opened. Protect yourself from the cold.

Pharmaceutical Name of Genazopt Ophthalmic Solution

General Pharmaceuticals Ltd

Generic of Genazopt Ophthalmic Solution

Brinzolamide